<DOC>
	<DOC>NCT00133224</DOC>
	<brief_summary>The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases with pain. Patients may have had up to one prior non-taxane chemotherapy treatment.</brief_summary>
	<brief_title>Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy Detectable metastases ECOG performance status ≤2 (Performance status of 3 if due to bone pain) Any Gleason score Only one prior treatment with systemic chemotherapy No prior treatment with gene therapy No prior immunotherapy for prostate cancer Taxane naïve Experiencing cancerrelated pain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Advanced Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone-refractory</keyword>
	<keyword>GVAX</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cells</keyword>
</DOC>